Nov. 29 (Bloomberg) -- Ranbaxy Laboratories Ltd.’s recall and production halt of its version of the cholesterol pill Lipitor won’t create a supply shortage, U.S. regulators said.
Ranbaxy has stopped making the generic pills while it investigates how glass particles got into the product, the Food and Drug Administration said today in a statement. The company, based near New Delhi, announced Nov. 23 it had recalled the medicine. The FDA said it hasn’t received any reports of patients being harmed.
To contact the reporter on this story: Drew Armstrong in New York at email@example.com;
To contact the editor responsible for this story: Reg Gale at firstname.lastname@example.org